Press Releases

Press Releases

  1. BTG plc: Completion of the Acquisition of Protherics PLC

  2. BTG Licensee Cougar Biotechnology Initiates Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer

  3. BTG plc: Interim Results for the Six Months Ended 30 September 2008

  4. BTG licenses novel anticancer compound to Onyx Pharmaceuticals

  5. Full Results of Varisolve® US Phase II Safety Study to be Presented at ACP

  6. BTG plc: Result of EGM

  7. BTG plc to Announce its Interim Results on 12 November 2008

  8. BTG plc: Final Phase II Results of Campath® Multiple Sclerosis Study Published

  9. BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Intended Date of Posting of Offer Documents

  10. BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Posting of Scheme Document/Receipt of Letters of Intent

  11. 18 September 2008: Recommended All Share Offer by BTG plc for Protherics plc

  12. BTG plc: Tolerx Initiates Dosing of Otelixizumab in a Phase III Clinical Trial in Type 1 Diabetes

  13. BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive

  14. BTG plc: Annual General Meeting and Interim Management Statement

  15. BTG Reports Successful Completion of Treatments in Varisolve® US Phase II Safety Study

  16. BTG plc: Acquisition of Protez Pharmaceuticals by Novartis

  17. BTG plc: Preliminary Results for the Year Ended 31 March 2008

  18. BTG Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients

  19. BTG plc: Close Period Update

  20. BTG plc: Positive Interim Report of Varisolve® Phase II Safety Study to be Presented at SIR 2008 Scientific Meeting

  21. BTG Initiates Clinical Study of Novel Multiple Sclerosis Treatment

  22. BTG plc Commences First Clinical Study of Novel Migraine Treatment

  23. BTG plc: Interim Management Statement

  24. Senexis Raises £3.7 Million from the Wellcome Trust and BTG to Further Develop its Small Molecule Alzheimer's Compounds